Medico Remedies FY26 Results and AGM Notice

Total Income stood at Rs 212.31 crore for FY 2025-26, compared to Rs 153.63 crore in the previous year. Profit After Tax rose to Rs 13.11 crore from Rs 10.09 crore reported in FY 2024-25.

Reader Takeaway: Robust top-line expansion drives 30% bottom-line growth, though investors face upcoming management remuneration hikes and past compliance issues.

What just happened

Medico Remedies has released its Annual Report for FY26 and issued notice for its 32nd AGM, to be held via video conferencing on September 22, 2026. The filing highlights significant year-on-year growth across key financial metrics.

Why this matters

The growth figures reflect strong operational momentum in the company's pharmaceutical formulation business. Investors are being asked to vote on the re-appointment of key leadership, including Chairman Haresh Mehta and Whole-Time Director Rishit Mehta, for a new three-year term.

Governance and Remuneration

The board has proposed remuneration revisions for Managing Director Harshit Mehta, alongside consultancy fees for Priyal Rishit Mehta and salary updates for Shweta Harshit Mehta, both capped at Rs 5 lakh per month. These items require shareholder approval at the AGM.

Risks to watch

The company previously incurred fines from BSE and NSE due to a vacancy in the Company Secretary and Compliance Officer role between August 2025 and February 2026. While the fines were paid, the event highlights past operational oversight.

What to track next

The company has not recommended a dividend for FY 2025-26. Shareholders should monitor the outcomes of the AGM votes regarding management compensation and long-term strategic direction as the firm integrates new ERP solutions for inventory management.